{
  "ticker": "LLY",
  "target_date": "2025-10-16",
  "actual_date": "2025-10-16",
  "collected_at": "2025-12-08T12:24:55.482970",
  "price": {
    "open": 823.86,
    "high": 833.48,
    "low": 814.17,
    "close": 818.1784057617188,
    "volume": 2272900,
    "change_1d_pct": -0.87,
    "change_7d_pct": -2.87,
    "change_30d_pct": 10.29
  },
  "technicals": {
    "rsi_14": 72.67,
    "sma_20": 794.36,
    "sma_50": 746.55,
    "macd": 22.412,
    "macd_signal": 23.033,
    "macd_histogram": -0.621,
    "bb_upper": 890.83,
    "bb_lower": 697.89,
    "price_vs_sma20_pct": 3.0,
    "price_vs_sma50_pct": 9.59,
    "volume_ratio": 0.59
  },
  "fundamentals": {
    "market_cap": 893874995200,
    "pe_ratio": 48.854485,
    "forward_pe": 44.003532,
    "price_to_book": 37.542168,
    "price_to_sales": 15.043386,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.33,
    "pct_from_52w_low": 59.85
  },
  "macro": {
    "spy": {
      "price": 660.64,
      "change_1d_pct": -0.68,
      "change_7d_pct": -1.85
    },
    "vix": {
      "level": 25.31,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 3.98
    },
    "dollar_index": {
      "level": 98.39
    },
    "gold": {
      "price": 4280.2
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing",
      "source": "Yahoo",
      "datetime": 1760649751,
      "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) stock fell 3.5% and Eli Lilly (NYSE:LLY) shares dropped 3% in after-hours trading Thursday following comments from President Trump regarding potential price reductions for popular weight loss medications.",
      "url": "https://finnhub.io/api/news?id=0844b575bcd9f9aecf53bc7945238ec1f665ecf0acb7af4e069bec07821d3031"
    },
    {
      "headline": "Johnson & Johnson\u2019s (JNJ) Stock Is Now Positioned To \u201cChallenge Eli Lilly,\u201d Says Jim Cramer",
      "source": "Yahoo",
      "datetime": 1760643448,
      "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the larges",
      "url": "https://finnhub.io/api/news?id=01ca43712277f5673183febd5d5540dda998468a717c506ecc8f8a8d574c70c8"
    },
    {
      "headline": "A Look at Eli Lilly\u2019s Valuation Following Landmark Orforglipron Phase 3 Results",
      "source": "Yahoo",
      "datetime": 1760642106,
      "summary": "Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood sugar control, meaningful weight loss, and cardiovascular improvements compared to both a rival medici",
      "url": "https://finnhub.io/api/news?id=fa332f05e4ef75ebc8808477786f9b7bbff2bfa22a6acee7b3119e48cfababac"
    },
    {
      "headline": "Guggenheim Reiterates Eli Lilly and (LLY) Buy Recommendation",
      "source": "Fintel",
      "datetime": 1760640485,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b7af5c091d81d762ce4cf9d86a5a2a7129348a89b720f2012eae064a77ea3376"
    },
    {
      "headline": "LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins",
      "source": "Yahoo",
      "datetime": 1760637300,
      "summary": "Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.",
      "url": "https://finnhub.io/api/news?id=b6656dc8dd77dacafed03a1e4ec30c4a8d7e7609817ca8888a62441ff8da9e97"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-10-14",
      "description": "xslF345X05/form4-10142025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000037/xslF345X05/form4-10142025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-10",
      "description": "xslF345X05/form4-10102025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000035/xslF345X05/form4-10102025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-09",
      "description": "xslF345X05/form4-10092025_041002.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000031/xslF345X05/form4-10092025_041002.xml"
    },
    {
      "form": "4",
      "date": "2025-10-08",
      "description": "xslF345X05/form4-10082025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000029/xslF345X05/form4-10082025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-07",
      "description": "xslF345X05/form4-10072025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000027/xslF345X05/form4-10072025_041001.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}